Final results from the phase III FLAURA2 trial demonstrate that adding platinum–pemetrexed chemotherapy to first-line osimertinib significantly improves overall survival (OS) in patients with EGFR-mutated advanced non–small-cell lung cancer (NSCLC). In the final overall survival analysis, median survival was 47.5 months with combination therapy compared with 37.6 months with osimertinib monotherapy, representing a 23% reduction in the risk of death. Although higher rates of grade 3 or greater adverse events were observed with the combination regimen, toxicities were largely chemotherapy-related and reversible. These findings establish osimertinib plus platinum–pemetrexed as a more effective first-line option for appropriate, fit patients and support treatment intensification beyond EGFR-targeted monotherapy.

Clinical Takeaway

First-line treatment with osimertinib + platinum-pemetrexed chemotherapy significantly improves OS compared with osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC, with increased but manageable toxicity.

Drug Profile & Mechanism

Agent: osimertinib + platinum-pemetrexed
Class:
- osimertinib: third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
- pemetrexed: antifolate antimetabolite chemotherapy
- carboplatin or cisplatin: platinum-based DNA-damaging cytotoxic chemotherapy
Mechanism of action:
- osimertinib: Irreversibly inhibits mutant EGFR (exon 19 deletions or exon 21 L858R mutation positive), blocking downstream signaling pathways that drive tumor growth and survival
- pemetrexed: inhibits multiple folate-dependent enzymes, disrupting RNA and DNA synthesis
- Platinum agents: induce DNA crosslinking and apoptosis through direct DNA damage
Route of administration:
- osimertinib: oral
- platinum-pemetrexed: intravenous
Dosing Schedule:
- osimertinib
  - 80 mg orally daily (continuous)
- pemetrexed
  - 500 mg/m2 on day 1 of 21 day cycle x 4 cycles (~3 months)
- carboplatin (AUC5)
  - AUC5 on day 1 of 21 day cycle x 4 cycles (~3 months)
- cisplatin
  - 75 mg/m2 on day 1 of 21 day cycle x 4 cycles (~3 months)
Target population: Patients with previously untreated, locally advanced or metastatic (stage IIIB–IV) non–small-cell lung cancer harboring EGFR exon 19 deletion or L858R mutation.

FLAURA2 Phase III trial Study Design (NCT04035486)

Study Type: Phase III, international, randomized, open-label trial
Population: 557 adults with previously untreated EGFR-mutated advanced NSCLC
Comparator: osimertinib monotherapy
Treatment Regimen: Osimertinib + platinum–pemetrexed vs osimertinib alone
Follow Up Duration:
- Patients followed until disease progression, death, or study completion
Primary and Key Secondary Assessments:
- Primary: PFS
- Secondary: OS

NOTE: Event-free survival(EFS) and pathologic complete response (pCR) are not applicable in this metastatic, non-surgical study.

Estimated study completion: 2025 (final OS analysis reported)
Key Endpoints:
- Primary:
  - PFS
- Secondary:
  - OS
  - Objective response rate
  - Duration of Response
  - Safety and tolerability

Efficacy Outcomes

Primary Endpoint Results:
- Prior analyses demonstrated significantly prolonged PFS with osimertinib + platinum-pemetrexed versus osimertinib monotherapy
Secondary Endpoint Results:
OS (Final Analysis):
- Median OS:
  - 47.5 months with combination therapy
  - 37.6 months with osimertinib alone
- Hazard ratio for death: 0.77 (95% CI, 0.61-0.96; P = 0.02)
pCR Rate: N/A

Regulatory Milestones

Approval Status: osimertinib monotherapy approved for first-line EGFR-mutated metastatic NSCLC
Regulatory Pathway: FLAURA2 provides confirmatory evidence supporting combination therapy as an intensified first-line option, rather than initial drug approval
Regulatory Review: Data support guideline updates and inform regulatory and labeling considerations for combination first-line therapy.

Safety

Overall AE Burden: Higher with combination therapy, consistent with chemotherapy exposure
Grade ≥3 Events:
- 70% with combination therapy
- 34% with monotherapy
Delayed Surgery: N/A
Delayed Adjuvant Treatment: N/A
Treatment-related deaths: Rare and balanced between treatment arms
Notable toxicity patterns:
- Increased hematologic toxicities
- Higher rates of fatigue and gastrointestinal adverse events
- Toxicities largely chemotherapy-related and reversible

Key Clinical Implications

✔ Establishes osimertinib plus platinum-pemetrexed as a more effective first-line strategy for eligible patients

✔ Demonstrates a clinically meaningful overall survival benefit

✔ Confirms manageable safety profile despite increased grade ≥ 3 events

✔ Supports individualized treatment intensification based on patient fitness

✔ Reinforces EGFR mutation-directed therapy as the foundation of care

Bottom Line

Adding platinum–pemetrexed chemotherapy to first-line osimertinib significantly improves survival in EGFR-mutated advanced NSCLC and represents a new benchmark for treatment intensification in appropriate patients.

Sources:

U.S. Food and Drug Administration. (2024, February 16). FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer
Jänne, P. A., Planchard, D., Kobayashi, K., Yang, J. C.-H., Liu, Y., Valdiviezo, N., Kim, T. M., Jiang, L., Kagamu, H., Yanagitani, N., Wang, J., Biswas, B., Poltoratskiy, A., Neron, Y., Rojas, C., Koubkova, L., Escriu, C., Ezeife, D. A., Mann, H., … Lee, C. K. (2025). Survival with osimertinib plus chemotherapy in EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 394(1), 27–38. https://doi.org/10.1056/NEJMoa2510308
U.S. National Library of Medicine. (2025). A Phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy as first-line treatment in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (FLAURA2) (ClinicalTrials.gov Identifier: NCT04035486). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04035486